Drugs / JNJ-69086420
last change Nov 2020 re-read 2 minutes ago

JNJ-69086420

Developed for
prostate neoplasm
Investigated by
Janssen Research & Development, LLC

Trials 1 · a red edge is where a trial was stopped

2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04644770 Nov 2020 → Dec 2026 expected adenocarcinoma, prostate neoplasm Janssen Research & Development, LLC Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as JNJ-69086420 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04644770